Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Optimization of Human Dose Prediction by Using Quantitative and Translational Pharmacology in Drug Discovery
Tjerk Bueters, Christopher R. Gibson, Sandra A. G. Visser
Future Medicinal Chemistry (2015) Vol. 7, Iss. 17, pp. 2351-2369
Closed Access | Times Cited: 24

Showing 24 citing articles:

Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations
Robert J. Young, Paul D. Leeson
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 15, pp. 6421-6467
Closed Access | Times Cited: 103
Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery
Adam Lucas, Joanne L. Sproston, Patrick Barton, et al.
Expert Opinion on Drug Discovery (2019) Vol. 14, Iss. 12, pp. 1313-1327
Closed Access | Times Cited: 101
Avibactam Pharmacokinetic/Pharmacodynamic Targets
Wright W. Nichols, Paul Newell, Ian A. Critchley, et al.
Antimicrobial Agents and Chemotherapy (2018) Vol. 62, Iss. 6
Open Access | Times Cited: 86
Large-Scale Compartmental Model-Based Study of Preclinical Pharmacokinetic Data and Its Impact on Compound Triaging in Drug Discovery
Peter Zhiping Zhang, Jeanine Ballard, Facundo Esquivel Fagiani, et al.
Molecular Pharmaceutics (2025)
Closed Access
Use of pharmacokinetic versus pharmacodynamic endpoints to support human dose predictions: implications for rational drug design and early clinical development
Rui Li, Tristan S. Maurer
Expert Opinion on Drug Discovery (2025)
Closed Access
Impact of Physicochemical Properties on Dose and Hepatotoxicity of Oral Drugs
Paul D. Leeson
Chemical Research in Toxicology (2018) Vol. 31, Iss. 6, pp. 494-505
Closed Access | Times Cited: 45
Contemporary Formulation Development for Inhaled Pharmaceuticals
Tomás Sou, Christel A. S. Bergström
Journal of Pharmaceutical Sciences (2020) Vol. 110, Iss. 1, pp. 66-86
Open Access | Times Cited: 35
Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
Tomás Sou, Jon Hansen, E. Liepinsh, et al.
Clinical Pharmacology & Therapeutics (2020) Vol. 109, Iss. 4, pp. 1063-1073
Open Access | Times Cited: 31
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery
W. Peter Wuelfing, Abdellatif El Marrouni, Maya P. Lipert, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 3, pp. 1685-1694
Closed Access | Times Cited: 16
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective
Harvey Wong, Tonika Bohnert, Valeriu Damian‐Iordache, et al.
Drug Discovery Today (2017) Vol. 22, Iss. 10, pp. 1447-1459
Closed Access | Times Cited: 21
Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles
John M. Sanders, Douglas C. Beshore, Joseph Culberson, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 16, pp. 6771-6780
Closed Access | Times Cited: 21
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
Junsheng Xue, Daming Kong, Ye Yao, et al.
Journal of Pharmaceutical Sciences (2020) Vol. 109, Iss. 10, pp. 3172-3180
Open Access | Times Cited: 17
The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD)
Wright W. Nichols, Patricia A. Bradford, Gregory G. Stone
Journal of Antimicrobial Chemotherapy (2022) Vol. 77, Iss. 9, pp. 2341-2352
Closed Access | Times Cited: 10
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model
Heinrich J. Huber, Hitesh Mistry
Journal of Pharmacokinetics and Pharmacodynamics (2023) Vol. 51, Iss. 2, pp. 169-185
Open Access | Times Cited: 5
Concept and application of the probability of pharmacological success (PoPS) as a decision tool in drug development: a position paper
Chao Chen, Xuan Zhou, Silvia Maria Lavezzi, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Phosphorylation of extracellular signal-regulated kinase as a biomarker for cannabinoid receptor 2 activation
Jingru Wang, Juehua Xu, Yanyan Peng, et al.
Heliyon (2018) Vol. 4, Iss. 11, pp. e00909-e00909
Open Access | Times Cited: 9
Assessment of translational risk in drug research: Role of biomarker classification and mechanism-based PKPD concepts
Sandra A. G. Visser, Tjerk Bueters
European Journal of Pharmaceutical Sciences (2017) Vol. 109, pp. S72-S77
Closed Access | Times Cited: 7
Leveraging model-informed approaches for drug discovery and development in the cardiovascular space
Marissa F. Dockendorf, Ryan Vargo, Ferdous Gheyas, et al.
Journal of Pharmacokinetics and Pharmacodynamics (2018) Vol. 45, Iss. 3, pp. 355-364
Open Access | Times Cited: 4
Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate
Jeanine Ballard, Parul S. Pall, Joshua D. Vardigan, et al.
Pharmaceutical Research (2020) Vol. 37, Iss. 10
Open Access | Times Cited: 4
Translational Pharmacokinetic–Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose
Jeanine Ballard, Parul S. Pall, Joshua D. Vardigan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 4
Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections
Irene Hernández-Lozano, Vincent Aranzana‐Climent, Sha Cao, et al.
Journal of Antimicrobial Chemotherapy (2024)
Open Access
Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy
Bennett Ma, Aline Barth, Carolyn McHale, et al.
Antiviral Research (2018) Vol. 151, pp. 1-3
Closed Access | Times Cited: 3
Impact of dosing schedule in animal experiments on compound progression decisions
Chao Chen
Drug Discovery Today (2018) Vol. 24, Iss. 2, pp. 371-376
Closed Access | Times Cited: 3
A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose
Iain Martin, Susan E. Hill, James Α. Baker, et al.
Drug Metabolism and Disposition (2016) Vol. 44, Iss. 8, pp. 1435-1440
Open Access | Times Cited: 2
Informing Decisions in Discovery and Early Development Research Through Quantitative and Translational Modeling
Tjerk Bueters, Christopher R. Gibson, Prajakti A. Kothare, et al.
Methods and principles in medicinal chemistry (2018), pp. 467-496
Closed Access
Page 1

Scroll to top